+34 620 10 75 37info@nanbiosis.com

Posts Taged nanomol

Nora Ventosa appointed Research Professor under the Materials Science

Nora Ventosa, the Scientific Director of NANBIOSIS U6 of Biomaterial Processing and Nanostructuring Unit (and IP of the NANOMOL Group of CIBERBBN at ICMAB-CSIC) has been appointed Research Professor in the last call of the Spanish National Reserach Council (CSIC)

This elective process for the selection and appointment of career civil servant, by internal promotion, in the Scale of Research Professors of Public Research Organisms had oppen 6 new positions for Professors under the Materials Science.

Nora Ventosa is a Chemical Engineer by the Institut Químic de Sarrià (IQS) and Doctor in Chemistry by the Universitat Ramon Llull. Her research is focused on green chemistry, soft materials and nanobiochemistry. She is devoted to develop and apply new methodologies, based on compressed fluids, in order to gain control of molecular self-assembly in solution.

Prof. Ventosa is also co-founder of the spin-off Nanomol Technologies, vicepresident of the Societat Catalana de Química (SCQ-IEC), member of the Administration Council of ACCIÓ, the Catalan Government agency for the promotion of the competitiveness within companies, and President of the TECNIO Research Association. She has participated, organized and directed more than 50 research projects, funded by different national and international agencies, public, private and industrial, including the European projects Smart4Fabry (Smart multifunctional GLA-nanoformulation for Fabry disease) or Phoenix (Open Innovation Test Bed for Enabling Pharmaceutical Innovative Products).

U6: Biomaterials processing and Nanostructuring unit

 Unit 6 of NANBIOSIS, on Biomaterials processing and Nanostructuring unit from CIBER-BBN, hosted at ICMAB-CSIC, with Scientific Director Nora Ventosa, from the Nanomol-Bio research group. The U6 gathers several laboratories, perfectly equipped, to perform the mission of this facility: the development, characterization, and large-scale production of molecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure. One example of Key-Enabling-Technology (KET) available in this unit in collaboration with the SME Nanomol Technologies (spin off of CSIC) is a simple and green one-step methodology, DELOS, based on the use of compressed fluids (CF), such as CO2, to prepare particulate materials with precise and reproducible structural characteristics at micro-, nano- and supramolecular levels (size, shape, internal structural gradients, supra­molecular organization and crystalline purity). This example shows one of the singularities of this unit is that counts with CF–based plants at different scales, from mL to L, which allow process development by QbD and process scale-up. Recently U6 NANBIOSIS, together with the Soft Scientific and Technical Service, was accredited with the ISO9001 certification for the standard quality control system. 

Congratulations Nora!

Read More

Nanomol group initiates contact with the AEMPS to bring a new treatment against venous leg ulcers to the clinic

Researchers of the Nanomol group, ICMAB-CSIC and CIBER-BBN members of the ICTS “NANBIOSIS”, specifically of the Biomaterial Processing and Nanostructuring unit (U6), together with the company Nanomol Technologies S.L. have begun a consultation process with the Spanish Association of Medicines and Health Products (AEMPS) to try and enter a new treatment in a clinical studies stage, to fight against venous ulcers in lower extremities. The study is carried out within the framework of the RIS3CAT NANONAFRES project.

Approximately, 80% of ulcers in lower extremities have associated pathologies of venous insufficiency and these wounds are usually recurrent. An open ulcer can take from weeks to years to close, increasing the risk of mortality and affecting the quality of life of patients who suffer from them, mostly elderly people. The solution proposed within the NANONAFRES project consists of a medicine for topical application based on the incorporation of a biomolecule, with skin regenerating activity, encapsulated in nanoparticles. This approach ensures the protection of the active substance, preventing its degradation, while allowing the controlled and direct release of the drug in the area of ​​the ulcer.

The NANONAFRES project, led by Nanomol Technologies SL, was born from the collaboration of the Nanomol group from ICMAB-CSIC with the companies Nanomol Technologies and BIOMED-LEITAT, the primary care centres EAP Osona Sur-Alt Congost SLP and the EAP Vallcarca-Sant Gervasi, public hospitals such as the Terrassa Health Consortium and the Maresme Health-Consortium Foundation and international research centres such as the Centro de Ingeniería Genética y Biotecnología de Cuba. This project, awarded with a RIS3CAT fund sponsored by the Generalitat of Catalonia, has a budget of 2.3 million euros and a duration of 3 and a half years.

This first consulting meeting with the AEMPS is a very important milestone in the process of developing any drug, in order to carry out clinical trials and transfer the system to the market, and thus bring the proposed treatment to the people who need it.

This approach will improve the effectiveness of current venous ulcers treatments, as well as the quality of life of patients, reducing the cost of medicines available today. In addition, the Nanomol group already has an internationally granted patent on this product, which demonstrates the novelty of this system and strengthens its position to reach the market through the partners present in this consortium and, in particular, through its spin-off Nanomol Technologies S.L.

Links of interest:

Article published on ICMAB’s site: http://icmab.es/nanomol-participa-al-projecte-nanonafres-de-la-comunitat-ris3cat-de-nous-dispositius-de-diagnostic-i-big-data-aplicades-a-la-salut

Article published on LEITAT’s site: https://projects.leitat.org/nanonafres/

Patent: “VESICLES COMPRISING EPIDERMAL GROWTH FACTOR AND COMPOSITIONS THEREOF” (WO2014019555)

Read More

Validation of a drug for foot ulcers in collaboration with Cuba

Nanomol, (Unit 6 of NANBIOSIS) has announced in Cuba that the process of clinical validation of a new drug developed and patented in collaboration with Center of Genetic Engineering and Biotechnology of Cuba, integrated in BioCubaFarma, has been initiated. The new drug is designed to improve the healing of foot ulcer in diabetics and could be on the market in five years.

The collaboration of the Center for Genetic Engineering and Biotechnology of Cuba with Nanomol, coordinating group of Unit 6 of NANBIOSIS, began in 2010. Cuban researchers had developed an effective product in wound healing in diabetics but the product had to be Administered with injections in the affected area. Nanomol obtained a nanoformulation with which it is possible to integrate the protein in a nanovesícula, so that the active principle of its degradation is protected once it is applied in the wound and, in addition, is obtained that the protein is released of suitable form. The results of the work have resulted in a patent and currently the process of validation and scaling of pharmaceutical production is being carried out to bring the product to market.

U6 of NANBIOSIS has played an important role in the development of this potential nanomedicine since it enabled a detailed characterization of several physico-chemical properties of the multifunctional nanovesicles used to construct it.

Validation of a drug for foot ulcers in collaboration with Cuba
Read More

Synergies produced in NANBIOSIS multiply the value of its services and allow its users to have results with faster and superior reliability due to proven experience of the scientists and technicians involved, says Jaume Veciana, Scientific Director of NANBIOSIS, in an interview at July 2016 CIBER-BBN Bulletin.

In this interview, Jaume Veciana assesses the functioning of this Singular Scientific-Technical Infrastructure and its contribution to research and anticipates some of the guidelines of the NANBIOSIS Strategic Plan 2017-2020, which includes a clear commitment to internationalization.

“The scientific-technical capabilities available at NANBIOSIS must be exploited without limitation to our country. Therefore we are clear that we must promote the activity of NANBIOSIS both academic and industrial sector in the European Union and other countries, either directly or in association with other similar organizations actions. Some such initiatives have already started but we believe it should be given further boost to internationalization. As an example we can mention the participation in the European project INFRAIA that aims to integrate regional and national research infrastructures existing in Europe under the Horizon 2020”

Professor Veciana also talks about NANOMOL, the research group coordinator of Unit 6 of NANBIOSIS, and the main applications of their findings in the fields of nanomedicine and biomaterials.

To know more

Synergies produced in NANBIOSIS multiply the value of its services and allow its users to have results with faster and superior reliability due to proven experience of the scientists and technicians involved, says Jaume Veciana, Scientific Director of NANBIOSIS, in an interview at July 2016 CIBER-BBN Bulletin.
Read More